LimFlow’s Percutaneous Deep Vein Arterialization (pDVA) System is enabling vascular specialists to offer new hope to patients suffering from Critical Limb Ischemia: a common, chronic, severe form of peripheral artery disease. “These patients have totally occluded below-the-knee (BTK) arteries and in many cases are days away from amputation,” says LimFlow CEO Dan Rose. “Our innovative technology allows vascular physicians to percutaneously convert the venous vascular ‘tree’ to arterial flow and immediately perfuse a foot with oxygenated blood, saving patients from amputation.”

- **URGENT CLINICAL NEED FOR NEW TREATMENT OPTION.** CLI is associated with a severe prognosis of high morbidity and mortality rates. One year after CLI has been diagnosed, 25% of patients are dead, and 30% are amputated. Indeed, the sicker patients, those with non-reconstructible distal arterial occlusive disease, are referred to in the scientific literature as the “no option” CLI patient population. These are patients whose arteries cannot be revascularized, and whose only treatment option until now has been major amputation.

- **INNOVATIVE TECHNOLOGY.** LimFlow is a novel endovascular, minimally invasive procedure designed to provide “no option” CLI patients with access to the benefits of venous arterIALIZATION, including increased rates of limb salvage, improved wound healing, and better quality of life without the disadvantages of invasive open surgery. The LimFlow pDVA System was invented by the company’s co-founder and interventional cardiovascular Key Opinion Leader, Martin Rothman, M.D., and refined in collaboration with Steven Kum, M.D., a vascular surgeon based in Singapore.

- **CE MARK IN PLACE, U.S. TRIALS UNDERWAY.** CE Mark was obtained in October 2016. A limited market release is in progress at 10 CLI “Centers of Excellence” in select European markets (Germany, Netherlands, Switzerland and Austria) for gathering strong post-market clinical data and experience. In the US, LimFlow has an IDE-approved Feasibility Study underway and expects to begin a Pivotal Clinical Trial in early 2018.

- **HIGHLY ENCOURAGING CLINICAL DATA.** As of April 2017, nearly 40 patients had been treated with the LimFlow procedure at 9 sites in Germany, Netherlands, France, Italy and Singapore. In all cases patients had ‘no option’ CLI and faced imminent amputation. All patients were “compassionate use” status with severe is-chemic ulcers or frank gangrene. Three patients are now 2 years post-treatment with no return of rest pain or wounds.

- **ATTRACTIVE BUSINESS FOR POTENTIAL ACQUIRERS.** About 270,000 ischemic lower limb amputations occur every year in the USA and Europe, and there are 160,000 new “no option” patients every year who could be eligible for the LimFlow procedure. This market opportunity is >$1B in a segment with no current or anticipated competition. The technology has been de-risked and fits perfectly “in the bag” of an established peripheral sales force and customer base. Peripheral disease is a growing market and a major area of investment for strategic medical device companies.

- **COMPPELLING EVIDENCE, NOW.** Continuing trials are expected to show the LimFlow pDVA System is designed to help increase the survival rate for “no option” CLI patients by avoiding amputation and associated high mortality and morbidity rates. Clinical data shows that both surgical and endovascular venous arterIALIZATION promote wound healing and help to avoid amputation by restoring blood flow to the peripheries. It is therefore expected that the LimFlow procedure will result in cost savings over time, given high costs associated with the amputation procedure, follow-up and management of complications, and chronic wound care management needs.

---

**The Problem with Amputations**

<table>
<thead>
<tr>
<th>Lethal</th>
<th>High perioperative mortality (4.2-15%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risky</td>
<td>High major complication rate (20-37%)</td>
</tr>
</tbody>
</table>

**The LimFlow “No Option” Segment**

| More than 3.2 M people with CLI in the US & EU today (800K incidence) |
| ~520K US & EU patients treated each year below the knee (BTK) for CLI |
| ~160K New “no option” CLI patients every year |

---

**CAUTION:** LimFlow Percutaneous Deep Vein Arterialization (pDVA) System for treating End-Stage Critical Limb Ischemia (CLI) is approved for sale in Europe.

**CONTACTS & KEY INFORMATION**

| Domicile | 95bis Boulevard Pereire Paris, France 75017 |
| Website  | www.limflow.com |
| Investors | Sofinnova, BPI France, Balexter, MDS |
| Focus   | Critical Limb Ischemia (CLI), a common and most severe form of Peripheral Arterial Disease (PAD) |
| Position| Avoid amputation in “no option” CLI patients |
| Initial Product, Clinical Need | LimFlow pDVA System is the only percutaneous approach delivering oxygenated blood to the foot via veins, giving new hope to the 270,000 annual patients facing amputation by treating CLI |
| Regulatory | CE Mark; EU commercialization and US IDE clinical program underway |

**LEADERSHIP TEAM**

Dan Rose
Chief Executive Officer

Tim Lenihan
Chief Technology Officer, Co-Founder

Sophie Humbert
Chief Operations Officer

Paul Limmer
Chief Financial Officer

Thomas Engels
Vice President, Clinical Affairs

**CLINICAL ADVISORS**

Steven Kum, MD
Vascular Surgeon, Chang Gen’l Hospital, Singapore

Roberto Ferraresi, MD
Cardiologist, Humanitas Gavazzeni, Milan, Italy

Jihad A. Mustapha, MD
Interventional Cardiologist, ACVAPC, MI

David Deaton, MD
Vascular Surgeon, Palmetto Health, SC

Peter A. Schneider, MD
Vascular Surgeon, Hawaii Permanente, HI

**Company Fact Sheet 2017**